Texas Health Atlas · Houston
Tvardi Therapeutics
Clinical-stage company developing oral small-molecule STAT3 inhibitors for inflammatory and proliferative diseases.
- Location
- Houston, Texas
- Focus
- Biotechnology
- Stage / status
- Clinical-stage
- Notes
- TTI-101 is in Phase 1b/2 development in hepatocellular carcinoma. In October 2025 the company reported that its Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis did not meet its goals.
- Website
- tvarditherapeutics.com
- Last reviewed
- Sep 29, 2026
Sources
- tvarditherapeutics.com/pipeline/
- ir.tvarditherapeutics.com/news-releases/news-release-details/tvardi-therapeutics-provides-update-preliminary-data-phase-2
Regulatory status is as stated by the company or its public filings on the review date; it changes. Work here? Send a correction or update.